Global Perennial Allergic Rhinitis Market - 2023-2030

Global Perennial Allergic Rhinitis Market - 2023-2030

Global Perennial Allergic Rhinitis Drugs Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.

Perennial rhinitis can be defined clinically as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhoea, occurring for an hour or more on most days throughout the year. Rhinitis is commonly managed by both primary and secondary care physicians. Although most cases can be diagnosed and treated in primary care, referral to secondary care is often necessary when patients do not respond to treatment or other diagnoses are suspected.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of allergic rhinitis

A global disease allergic rhinitis (AR) affects a huge proportion of people around the world. Allergic rhinitis is diagnosed with a group of symptoms affecting the nose. These symptoms occur when people breathe in something they are allergic to, such as dust, animal dander or pollen.

Changes in genetic factors are unlikely to be the underlying cause of the rise in allergic diseases since the increases in allergic rhinitis and asthma occurred relatively rapidly. Instead, multiple environmental factors may have played a role. These include improvements in hygiene, eradication of most parasitic worm infections, changes in home heating and ventilation, and a decline in physical activity and alterations in diet due to lifestyle changes.

The rise in the prevalence of allergic rhinitis is one of the significant key factors that drive the saline spray market during the forecast period. For instance, according to the article published in the National Library of Medicine 2023, the prevalence of AR cases ranged from 1.83 to 9.23% between 2017 and 2022. There was a significant drop of 21.38 to 70.22% between the pre- and post-COVID-19 pandemic. Males were more prevalent in the 6 to 18-year-olds than females. Thus, the above factors help to drive market growth during the forecast period.

Furthermore, ongoing extensive R&D activities for the development of more effective products and formulations, changes in environmental conditions, increasing pollution, rising number of patients, and changes in lifestyle are proving the major driving factors for the perennial allergic rhinitis market.

Market Dynamics: Restraint

Allergic rhinitis is a serious health condition that can lead to sleep disturbances, fatigue, irritability, depression, and difficulty paying attention. If left untreated, it can become chronic and lead to complications such as nasal inflammation, sinusitis, otitis media, sleep apnea, upper respiratory tract infection, dental problems, and eustachian tube dysfunction. It is also linked to increased chances of developing asthma, flares, worsening symptoms, and difficult-to-control asthma in those with existing asthma.

Segment Analysis

The global perennial allergic rhinitis drugs market is segmented based on drug class, route of administration, distribution channel and region.

The anti-histamines segment from the drug class segment accounted for approximately 41.7% of the perennial allergic rhinitis drugs market share

The anti-histamines segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Antihistamines are a pharmaceutical class of drugs that act to treat histamine-mediated conditions. There are two main classes of histamine receptors: H-1 receptors and H-2 receptors. Antihistamine drugs that bind to H-1 receptors are generally used to treat allergies and allergic rhinitis.

For instance, in June 2021, the U.S. Food and Drug Administration approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.

Geographical Analysis

Europe accounted for approximately 31.4% of the market share in 2022

Europe is estimated to hold about 31.4% of the total market share throughout the forecast period, owing to the rise in the prevalence of perennial allergic rhinitis, novel drug launches, rise in research and development, well-established market players, collaborations and acquisition with key players and others help this region to be having highest market share during the forecast period.

For instance, in April 2021, Glenmark Pharma stated that it is concluding the final, national phase of its marketing approval application process to launch its nasal spray Ryaltris in 17 countries in the European Union (EU). Glenmark said Ryaltris is now approved in Europe for the first-line treatment of allergic rhinitis in patients over 12 years of age. Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

COVID-19 Impact Analysis

A study conducted by an investigative otolaryngology group they found that many patients with allergic rhinitis symptoms worsened due to increased exposure to indoor allergens and discontinuation of immunotherapy during COVID-19 lockdowns. The study emphasizes the importance of long-term management, primary prevention, and control through allergen avoidance measures, pharmacotherapy, and allergen-SIT. Environmental factors are critical in AR pathogenesis, and immunotherapy remains the only treatment that alters the disease's natural history.

Market Segmentation

By Drug Class
• Anti Histamines
• Steroids
• Decongestants
• Allergen Immunotherapy formulations
• Others

By Route of Administration
• Oral
• Nasal
• Intramuscular

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include AdenHealthcare, Niprojmipharma, Krosyl Pharma, Sanis Health Inc, Hanmi Pharma, Johnson & Johnson Consumer Inc, Bristol Laboratories Ltd, GSK, Nutra Respiro, Bayer Canada and among others.

Key Developments

In July 2023, Altamira Therapeutics Ltd, a company dedicated to developing therapeutics that address important unmet medical needs, stated that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.

Why Purchase the Report?
• To visualize the global perennial allergic rhinitis drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of perennial allergic rhinitis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global perennial allergic rhinitis drugs market report would provide approximately 61 tables, 58 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies